Results 161 to 170 of about 145,148 (243)

Evaluating Thiram‐Induced Embryotoxicity Using Integrated In Silico, In Vitro, and Transcriptomic Approaches

Environmental Toxicology, EarlyView.
ABSTRACT Long‐term exposure to low‐dose food contact materials (FCMs) has raised concerns regarding developmental toxicity. In the present study, we prioritized FCMs with potential developmental toxicity using a weight‐of‐evidence computational model, which predicted 127 chemicals to be of high concern.
Chia‐Chi Ho, Chun‐Wei Tung, B. Linju Yen, Chen‐Yi Weng, Ju‐Hsin Hsu, Ming‐Hsien Tsai, Salim Arrokhman, Pinpin Lin   +7 more
wiley   +1 more source

Guillain–Barre Syndrome With Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation

The Kaohsiung Journal of Medical Sciences, EarlyView.
Chin‐Mu Hsu, Ping‐Hsuan Lin, Chia‐Hsuan Chiu, Hui‐Hua Hsiao   +3 more
wiley   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

[Chinese expert consensus on the diagnosis and treatment of plasma cell leukemia (2025)]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Multiple Myeloma Expert Committee of Chinese Society of Clinical Oncology (CSCO), Myeloma & Plasma Cell Disease Group, Hematology Oncology Committee of China Anti-Cancer Association (CACA), Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association.   +5 more
europepmc   +1 more source

Nonthermal plasma approaches for combating implant‐associated infections: A compendious review

VIEW, EarlyView.
Implant‐associated infections pose serious clinical challenges. Non‐thermal plasma (NTP) modifications overcome this bottleneck in distinct ways relative to traditional sterilization methods. Gas‐phase plasmas generate highly energetic species, UV radiation and reactive oxygen/nitrogen species (RONS), which alter the implant surface properties.
A. M. Trimukhe, Satish Rojekar, Amol Gholap, K. Navaneetha Pandiyaraj, Mukesh Patekar, Claudia Riccardi, R. R. Deshmukh, Tomáš Kovářík, Kalim Deshmukh   +8 more
wiley   +1 more source

A Clinical Perspective on Plasma Cell Leukemia: A Single-Center Experience. [PDF]

Cancers (Basel)
Li AY, Kamangar F, Holtzman NG, Rapoport AP, Kocoglu MH, Atanackovic D, Badros AZ.   +6 more
europepmc   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia. [PDF]

Hematol Oncol
Gregorova J, Vlachova M, Vychytilova-Faltejskova P, Dostalova A, Ruzickova T, Vecera M, Radova L, Pospichalova V, Sladecek S, Hyzdalova M, Kotaskova J, Jarosova M, Masek J, Benesova K, Jarkovsky J, Rihova L, Bezdekova R, Almasi M, Boichuk I, Stork M, Pour L, Sevcikova S.   +21 more
europepmc   +1 more source

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

VIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf, Yara Mashal, Afeefa Rao, Nasar Ata, Arun K. Iyer, Farhan Shah   +5 more
wiley   +1 more source

Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report. [PDF]

Front Immunol
Bernardi C, Beauverd Y, Tran TA, Maulini M, Mappoura M, Morin S, Simonetta F, Cairoli A, Auner HW, Samii K, Chalandon Y, de Ramon Ortiz C.   +11 more
europepmc   +1 more source